Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | HTR2C | P28335 | 4/20 | 0.40 |
| ▸ | HTR2B | P41595 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30873752 | 0.87 | TACR1 (0.43) | PARP1HTR2AHTR2CHTR2BNR1H2 | |
| SCHEMBL5333905 | 0.87 | HTR2C (0.47) | PARP1HTR2AHTR2CHTR2BNR1H2 | |
| SCHEMBL30502301 | 0.86 | HTR2C (0.44) | LMNAPARP1HTR2AHTR2CHTR2B | |
| SCHEMBL31556646 | 0.85 | NR1H2 (0.53) | PARP1HTR2AHTR2CHTR2BNR1H2 | |
| SCHEMBL30931055 | 0.84 | PARP1 (0.42) | ALDH1A1LMNATP53GLAPARP1 | |
| SCHEMBL29747260 | 0.83 | ALDH1A1 (0.52) | ALDH1A1LMNATP53GLATSHR | |
| SCHEMBL18284749 | 0.83 | DPP4 (0.43) | RAD52HTR2AHTR2CHTR2BDPP4 | |
| SCHEMBL27747418 | 0.82 | NR1H2 (0.38) | ALDH1A1LMNAPARP1HTR2AHTR2C | |
| SCHEMBL27887751 | 0.82 | NR1H2 (0.38) | ALDH1A1LMNAPARP1HTR2AHTR2C | |
| SCHEMBL27904545 | 0.82 | NR1H2 (0.38) | ALDH1A1LMNAPARP1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| EP-1989188-B1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2015-07-22 | — | — | EP | disclosed |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | disclosed |
| EP-2562168-B1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2014-04-16 | — | — | EP | disclosed |
| US-20140038945-A1 | PIPERAZINE PDE4 INHIBITORS AND USES THEREOF | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2014-02-06 | — | — | US | disclosed |
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | disclosed |
| US-8501745-B2 | Piperazine PDE4 inhibitors and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-08-06 | — | — | US | disclosed |
| EP-2562168-A1 | Therapeutic piperazines as PDE4 inhibitors | Helicon Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8338405-B2 | Therapeutic piperazines | DART NEUROSCIENCE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | disclosed |
| US-20110065688-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE LLC | 2011-03-17 | — | — | US | disclosed |
| US-20110065689-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | disclosed |
| US-7829713-B2 | Therapeutic piperazines | HELICON THERAPEUTICS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-1989188-A1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | Helicon Therapeutics, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007100852-A1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | HELICON THERAPEUTICS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070203124-A1 | Therapeutic Piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | RAD52 3539/4885ALDH1A1 1228/4885LMNA 2956/4885 |
| US-20070203124-A1 | Therapeutic Piperazines | PDE4A, PDE4B, PDE12 | RAD52 4140/4885ALDH1A1 838/4885LMNA 2466/4885 |
| US-20110065688-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE12 | RAD52 4140/4885ALDH1A1 838/4885LMNA 2466/4885 |
| US-20110065689-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE12 | RAD52 4140/4885ALDH1A1 838/4885LMNA 2466/4885 |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | RAD52 3539/4885ALDH1A1 1228/4885LMNA 2956/4885 |
| US-20140038945-A1 | PIPERAZINE PDE4 INHIBITORS AND USES THEREOF | PDE4A, PDE12, PDE4B | RAD52 4049/4885ALDH1A1 614/4885LMNA 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.